Residency · Residency · Medicine Pediatrics
Chronic Kidney Disease-Mineral Bone Disorder in Growing and Aging Skeletons
Introduction
Chronic kidney disease-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism arising from CKD. It encompasses abnormalities in calcium, phosphorus, PTH, and vitamin D metabolism, along with bone disease and vascular calcification. In children, CKD-MBD disrupts skeletal growth, linear growth, and development. In adults, it accelerates cardiovascular disease and fracture risk. Med-peds physicians must understand the pathophysiology, monitoring, and age-appropriate management of this condition.
Pathophysiology
The CKD-MBD Axis
Declining GFR leads to phosphorus retention, reduced 1,25-dihydroxyvitamin D synthesis, and decreased calcium absorption. FGF23 rises early (CKD stage 2-3), promoting phosphaturia and suppressing 1-alpha-hydroxylase. Secondary hyperparathyroidism develops as PTH increases to maintain calcium and phosphorus homeostasis. Elevated FGF23 and PTH contribute to left ventricular hypertrophy and cardiovascular mortality. Progressive disease leads to tertiary hyperparathyroidism with autonomous PTH secretion.
Bone Disease Classification (Renal Osteodystrophy)
High-turnover disease (osteitis fibrosa cystica): Driven by elevated PTH; increased bone resorption and formation. Low-turnover disease (adynamic bone disease): Over-suppression of PTH; increased fracture risk; more common in adults, particularly diabetics. Osteomalacia: Defective mineralization due to vitamin D deficiency or aluminum accumulation. Mixed uremic osteodystrophy: Features of both high and low turnover. Gold standard diagnosis: Bone biopsy with tetracycline labeling (rarely performed in practice)
Pediatric-Specific Considerations
Growth Impairment
CKD-MBD is a major contributor to short stature in children with CKD. Growth failure results from metabolic acidosis, nutritional deficiency, GH resistance, and bone disease. Growth hormone therapy is indicated for children with CKD and persistent growth failure despite optimized nutrition and metabolic control. Rickets-like changes: Widened, frayed, cupped metaphyses on radiographs; genu valgum or varum deformities.
Bone Development
The growing skeleton is uniquely vulnerable; growth plate disturbances lead to permanent deformity. Slipped capital femoral epiphysis (SCFE) is a recognized complication of renal osteodystrophy in children. Skeletal deformities may require orthopedic intervention if medical management is insufficient. Peak bone mass acquisition is impaired, increasing lifelong fracture risk.
Monitoring in Children
Calcium, phosphorus, alkaline phosphatase: Starting at CKD stage 2; frequency increases with advancing CKD. PTH: Measured starting at CKD stage 3; target levels are stage-dependent (KDIGO guidelines) 25-hydroxyvitamin D: Maintain >30 ng/mL; supplement with cholecalciferol or ergocalciferol. Radiographs of wrists and knees: Assess for rickets-like changes and growth plate abnormalities. Growth velocity monitoring with attention to height velocity Z-scores.
Adult-Specific Considerations
Cardiovascular Implications
Vascular calcification: Both FGF23 and hyperphosphatemia are independent risk factors for cardiovascular mortality. Coronary artery calcification is prevalent even in young adults with CKD. Calciphylaxis: Rare but devastating condition with calcification of small dermal vessels leading to ischemic skin necrosis; associated with warfarin use, obesity, and high calcium-phosphorus product. CKD-MBD management is integral to cardiovascular risk reduction in CKD.
Fracture Risk
CKD patients have 2-4 times higher fracture risk than the general population. DXA has limited utility in CKD stages 4-5 due to inability to distinguish renal osteodystrophy subtypes. Fractures in CKD patients are associated with higher morbidity and mortality. Bisphosphonates are generally avoided in CKD stage 4-5 due to adynamic bone disease risk; denosumab may cause severe hypocalcemia in advanced CKD.
Monitoring in Adults
Calcium, phosphorus: Every 6-12 months in CKD 3; every 3-6 months in CKD 4-5 and dialysis. PTH: Every 6-12 months in CKD 3-5; every 3-6 months on dialysis. Target PTH on dialysis: 2-9 times the upper limit of normal (KDIGO) Alkaline phosphatase: Trends help assess bone turnover activity.
Management
Phosphorus Control
| Agent | Type | Advantages | Disadvantages |
|---|---|---|---|
| Calcium carbonate | Calcium-based binder | Inexpensive; corrects hypocalcemia | Vascular calcification risk; hypercalcemia |
| Calcium acetate | Calcium-based binder | Better phosphorus binding per calcium load | Same calcification concerns |
| Sevelamer | Non-calcium polymer | No calcium load; may lower LDL | Pill burden; GI side effects; cost |
| Lanthanum carbonate | Non-calcium binder | Effective; chewable | Long-term tissue deposition concerns |
| Sucroferric oxyhydroxide | Iron-based binder | Low pill burden; effective | Dark stools; GI side effects |
Dietary phosphorus restriction: Limit to 800-1000 mg/day; prioritize reducing processed food and additive phosphorus. Phosphate binders: Calcium-based (calcium carbonate, calcium acetate) -- limit use due to vascular calcification risk; non-calcium-based (sevelamer, lanthanum, sucroferric oxyhydroxide) preferred in adults. In children, palatability and pill burden affect adherence; liquid formulations and binder choice are important. Dialysis adequacy contributes to phosphorus removal.
Vitamin D Therapy
Nutritional vitamin D (cholecalciferol/ergocalciferol): Replete deficiency in all CKD stages. Active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol): For secondary hyperparathyroidism in CKD stages 3-5. Monitor calcium closely during active vitamin D therapy to avoid hypercalcemia. Paricalcitol and doxercalciferol may have less calcemic effect than calcitriol.
Calcimimetics
Cinacalcet: Allosteric activator of the calcium-sensing receptor; lowers PTH, calcium, and phosphorus. Used in dialysis patients with secondary hyperparathyroidism not responsive to other therapies. Etelcalcetide: IV calcimimetic administered at dialysis sessions; improves adherence. Not approved for pediatric use, though off-label use occurs in refractory cases.
Parathyroidectomy
Indicated for refractory hyperparathyroidism unresponsive to medical therapy. Subtotal or total parathyroidectomy with autotransplantation. Post-surgical hungry bone syndrome: Severe hypocalcemia requiring aggressive calcium and vitamin D supplementation.
Clinical Pearls
FGF23 elevation is the earliest detectable abnormality in CKD-MBD, preceding changes in calcium, phosphorus, or PTH. In children, growth failure and rickets-like skeletal changes are hallmarks of CKD-MBD and require aggressive management. Vascular calcification in adults with CKD is an active, regulated process driven by hyperphosphatemia and is not simply passive calcium deposition. Over-suppression of PTH leads to adynamic bone disease with increased fracture risk; the target is a range, not the lowest possible value. Transition of pediatric CKD patients to adult care must include transfer of CKD-MBD management plans, growth history, and skeletal monitoring.
References
- KDIGO. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. Kidney Int Suppl. 2017;7(1):1-59.
- Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol. 2013;33(2):169-179.
- Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
- Bacchetta J, Schmitt CP, Ariceta G, et al. Recommendations for the management of CKD-MBD in children with CKD stages 4-5 and on dialysis. Pediatr Nephrol. 2023;38(11):3539-3557.